Protalix BioTherapeutics (PLX) Operating Expenses (2010 - 2026)

Protalix BioTherapeutics has reported Operating Expenses for 17 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 79.15% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $16.4 million (down 28.44% YoY), and the FY2025 full-year result was $21.0 million, up 18.38% from the prior year.
• Operating Expenses for Q1 2026 stood at $1.3 million, down from $2.6 million in the prior quarter.
• The five-year high for Operating Expenses was $11.9 million in Q1 2022, with the low at $1.3 million in Q1 2026.
• Average Operating Expenses over 5 years is $7.0 million, with a median of $7.4 million recorded in 2024.
• Year-over-year, Operating Expenses jumped 38.57% in 2025 and tumbled 79.15% in 2026.
• Tracing PLX's Operating Expenses over 5 years: stood at $8.7 million in 2022, then retreated by 16.87% to $7.2 million in 2023, then tumbled by 73.8% to $1.9 million in 2024, then soared by 38.57% to $2.6 million in 2025, then sank by 52.28% to $1.3 million in 2026.
• The last three Operating Expenses figures came in at $1.3 million (Q1 2026), $2.6 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.

Peer Comparison